Synthetic lethal and resistance interactions with BET bromodomain inhibitors in triple-negative breast cancer

BET bromodomain inhibitors (BBDI) are candidate therapeutic agents in triple-negative breast cancer (TNBC) and other cancer types, but inherent and acquired resistance to BBDIs limit their potential clinical use. Using CRISPR and small molecule inhibitor screens combined with comprehensive molecular...

詳細記述

保存先:
書誌詳細
出版年:Mol Cell
主要な著者: Shu, Shaokun, Wu, Hua-Jun, Ge, Jennifer Y., Zeid, Rhamy, Harris, Isaac S., Jovanović, Bojana, Murphy, Katherine, Wang, Binbin, Qiu, Xintao, Endress, Jennifer E., Reyes, Jaime, Lim, Klothilda, Font-Tello, Alba, Syamala, Sudeepa, Xiao, Tengfei, Reddy Chilamakuri, Chandra Sekhar, Papachristou, Evangelia K., D’Santos, Clive, Anand, Jayati, Hinohara, Kunihiko, Li, Wei, McDonald, Thomas O., Luoma, Adrienne, Modiste, Rebecca J., Nguyen, Quang-De, Michel, Brittany, Cejas, Paloma, Kadoch, Cigall, Jaffe, Jacob D., Wucherpfennig, Kai W., Qi, Jun, Liu, X. Shirley, Long, Henry, Brown, Myles, Carroll, Jason S., Brugge, Joan S., Bradner, James, Michor, Franziska, Polyak, Kornelia
フォーマット: Artigo
言語:Inglês
出版事項: 2020
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7306005/
https://ncbi.nlm.nih.gov/pubmed/32416067
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molcel.2020.04.027
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料